Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012172 | 1.00 | HCRTR2 (0.47) | HCRTR2HCRTR1EPHX2KMT2AALOX15 | |
| SCHEMBL2010776 | 0.86 | HCRTR1 (0.47) | HCRTR2HCRTR1EPHX2KMT2AALOX15 | |
| SCHEMBL13138941 | 0.86 | EPHX2 (0.48) | HCRTR2HCRTR1EPHX2KMT2AALOX15 | |
| SCHEMBL2011272 | 0.85 | HCRTR1 (0.62) | HCRTR2HCRTR1HDAC3HDAC1 | |
| SCHEMBL6919279 | 0.83 | HCRTR1 (0.45) | HCRTR2HCRTR1ROCK1HDAC3HDAC1 | |
| SCHEMBL2014608 | 0.83 | EPHX2 (0.49) | HCRTR2HCRTR1EPHX2KMT2AALOX15 | |
| SCHEMBL2010959 | 0.83 | EPHX2 (0.45) | HCRTR2HCRTR1EPHX2KMT2AALOX15 | |
| SCHEMBL2015188 | 0.83 | EPHX2 (0.45) | HCRTR2HCRTR1EPHX2KMT2AALOX15 | |
| SCHEMBL2053851 | 0.82 | HCRTR1 (0.53) | HCRTR2HCRTR1EPHX2KMT2AALOX15 | |
| SCHEMBL2016308 | 0.82 | HCRTR1 (0.53) | HCRTR2HCRTR1EPHX2KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | claimed |
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | HCRTR2 3029/4885HCRTR1 3230/4885EPHX2 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.